Treprostinil

Treprostinil
Clinical data
Trade names	Remodulin, Orenitram, Tyvaso, others
AHFS/Drugs.com	Monograph
License data	US DailyMed: Treprostinil;
Pregnancy; category	AU: B3;
Routes of; administration	Subcutaneous, intravenous, inhalation, by mouth
ATC code	B01AC21 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~100%
Metabolism	Substantially metabolized by the liver
Elimination half-life	4 hours
Excretion	Urine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%)
Identifiers
	IUPAC name (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid;
CAS Number	81846-19-7 ;
PubChem CID	6918140;
IUPHAR/BPS	5820;
DrugBank	DB00374 ;
ChemSpider	5293353 ;
UNII	RUM6K67ESG;
KEGG	D06213 ; D08628 ;
ChEBI	CHEBI:50861 ;
ChEMBL	ChEMBL1201254 ;
CompTox Dashboard (EPA)	DTXSID901021654 ;
ECHA InfoCard	100.236.149
Chemical and physical data
Formula	C23H34O5
Molar mass	390.520 g·mol−1
	InChI InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1 ; Key:PAJMKGZZBBTTOY-ZFORQUDYSA-N ;
	(what is this?) (verify)

Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of pulmonary arterial hypertension.

Treprostinil was approved for use in the United States in May 2002.